true true 0001173313 0001173313 2024-02-08 2024-02-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K/A

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 17, 2024 (February 8, 2024)

 

ABVC BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-40700   26-0014658
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

44370 Old Warm Springs Blvd.

Fremont, CA

   94538
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number including area code: (510) 668-0881

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol   Name of each exchange on which registered
Common Stock, par value $0.001 per share   ABVC   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 1.01 Entry into Material Definitive Agreements 

Item 1.02 Termination of a Material Definitive Agreements 

 

On February 8, 2024, ABVC BioPharma, Inc. (the “Company”) filed the initial Current Report on Form 8-K to disclose that it entered into a definitive agreement with Shuling Jiang (“Jiang”), pursuant to which Jiang was going to transfer the ownership of certain land she owns located at Taoyuan City, Taiwan (the “Land”) to the Company (the “Agreement”). Jiang is a director of the Company, is married to TS Jiang, the Company’s Chief Strategic Office and owns approximately 10% of the Company’s issued and outstanding shares of common stock.

On May 16, 2024, the Company’s board of directors determined that it was in the best interest of the Company and its shareholders to terminate the Agreement and not proceed with the transfer of land ownership at this time; the Company may reconsider the transaction at a later date.

 

Neither this Current Report on Form 8-K, nor any exhibit attached hereto, is an offer to sell or the solicitation of an offer to buy the Securities described herein. Such disclosure does not constitute an offer to sell, or the solicitation of an offer to buy nor shall there be any sales of the Company’s securities in any state in which such an offer, solicitation or sale would be unlawful. The securities mentioned herein have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act and applicable state securities laws.

 

Item 9.01 Exhibits

 

(d) Exhibits

 

Exhibit No.   Description
104   Cover Page Interactive Data File, formatted in Inline XBRL

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ABVC BioPharma, Inc.
   
May 17, 2024 By: /s/ Uttam Patil
    Uttam Patil
    Chief Executive Officer

 

 

v3.24.1.1.u2
Cover
Feb. 08, 2024
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag true
Amendment Description true
Document Period End Date Feb. 08, 2024
Entity File Number 001-40700
Entity Registrant Name ABVC BIOPHARMA, INC.
Entity Central Index Key 0001173313
Entity Tax Identification Number 26-0014658
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 44370 Old Warm Springs Blvd.
Entity Address, City or Town Fremont
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94538
City Area Code (510)
Local Phone Number 668-0881
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ABVC
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Grafico Azioni ABVC BioPharma (NASDAQ:ABVC)
Storico
Da Dic 2024 a Gen 2025 Clicca qui per i Grafici di ABVC BioPharma
Grafico Azioni ABVC BioPharma (NASDAQ:ABVC)
Storico
Da Gen 2024 a Gen 2025 Clicca qui per i Grafici di ABVC BioPharma